Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028. After running into ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities. It has nominated a lead candidate in the in vivo ...

The Boston Red Sox wrapped up their series in Seattle on Sunday with a 3-1 loss to the Mariners, unable to complete the sweep despite another strong outing from the pitching staff. The defeat dropped ...

Shares in Moderna rose 3.5% to $63.96 at market open on 18 June following the vote. Credit: Lutsenko_Oleksandr/Shutterstock.com. Moderna’s mRNA vaccine for ...